首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1099953篇
  免费   74671篇
  国内免费   1434篇
耳鼻咽喉   15447篇
儿科学   35740篇
妇产科学   29668篇
基础医学   157948篇
口腔科学   30192篇
临床医学   97068篇
内科学   208610篇
皮肤病学   25177篇
神经病学   84068篇
特种医学   44020篇
外国民族医学   214篇
外科学   166735篇
综合类   21844篇
现状与发展   1篇
一般理论   270篇
预防医学   75922篇
眼科学   25020篇
药学   87462篇
  7篇
中国医学   2823篇
肿瘤学   67822篇
  2019年   8113篇
  2018年   11731篇
  2017年   9266篇
  2016年   10576篇
  2015年   11765篇
  2014年   15925篇
  2013年   23096篇
  2012年   31789篇
  2011年   33638篇
  2010年   19650篇
  2009年   18544篇
  2008年   31162篇
  2007年   33326篇
  2006年   33930篇
  2005年   32298篇
  2004年   30829篇
  2003年   29594篇
  2002年   28489篇
  2001年   60779篇
  2000年   62283篇
  1999年   51608篇
  1998年   12778篇
  1997年   11256篇
  1996年   11226篇
  1995年   10516篇
  1994年   9521篇
  1993年   9039篇
  1992年   38182篇
  1991年   36695篇
  1990年   36158篇
  1989年   34632篇
  1988年   31199篇
  1987年   30358篇
  1986年   28579篇
  1985年   26793篇
  1984年   19439篇
  1983年   16307篇
  1982年   8944篇
  1979年   17273篇
  1978年   11580篇
  1977年   10386篇
  1976年   8990篇
  1975年   10223篇
  1974年   11846篇
  1973年   11436篇
  1972年   10894篇
  1971年   10224篇
  1970年   9385篇
  1969年   9061篇
  1968年   8021篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional...  相似文献   
3.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
4.
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation.  相似文献   
5.
6.
7.
8.
9.
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号